The European Society for Medical Oncology (ESMO) Congress 2025 brought leading oncology experts together to explore the latest advances shaping cancer care worldwide. Fast Five highlights key insights captured live from the Congress.
In this episode, Alina Sturdza, Radiation Oncologist, shares her perspective on pivotal developments in radiation oncology, discussing both promising advances and important lessons from recent trials. From dose de-escalation efforts in head and neck cancer to the evolving role of radiotherapy in oligometastatic disease and cervical cancer, Sturdza reflects on how innovation is redefining treatment strategies and patient outcomes.
Key discussion points include:
- Lessons from radiation dose de-escalation trials
- Oligometastatic disease expands curative radiotherapy
- EMBRACE trials redefine cervical cancer radiotherapy
- Integrating radiotherapy with systemic immunotherapies
Read the EMJ Oncology Journal for more cutting-edge insights from ESMO 2025, including expert interviews and in-depth analysis of the research shaping the future of oncology.
Disclosure: Sturdza has received support for travel and accomodation from ESMO for the ESMO Congress 2025; research grants from Elekta AB and Varian Medical Systems, with payment to The Medical University of Vienna, and grants for the GEC ESTRO EuroBT Fellowship from Elekta AB and Varian Medical Systems, with payment to ESTRO; teaching honoraria from the BrachyAcademy, Elekta AB, MSD, and GSK; partial support for meetings from the University of Vienna, ESGO, and ESTRO; participated on a Data Safety Monitoring Board or Advisory Board for GROINSS-V III; and been a committee member for EC ESTRO and GEC ESTRO.
